RxDoctor Payments Data

Kevin Fleming, MD

Internal Medicine · Tucson, AZNPI 1912948167

Payments from drug & device makers

$530in general payments, 2019–2025

Across 15 payments — averaging $35.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$140
  • Medtronic$105
  • Teleflex LLC$104
  • Pfizer$33
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$26
  • Novartis$25
  • plus $97 from 5 others

What the payments were for

  • Food & beverage$530100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$530 in reported general payments places this provider in the 65th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$37,458
Medicare patients
211
Services billed
366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$25,845
OzempicSemaglutide15$16,527
JardianceEmpagliflozin14$12,147
Atorvastatin Calcium102$837
Omeprazole32$712
Rosuvastatin Calcium56$574
Tramadol Hcl ErTramadol Hcl12$572
Losartan Potassium61$512
Levothyroxine Sodium63$475
Gabapentin23$446
Potassium Chloride26$350
Amlodipine Besylate48$348
Metoprolol Succinate22$343
Tamsulosin Hcl32$274
Levetiracetam11$265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$25,84517 claims
Novo NordiskOzempic$140$16,52715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →